Advertisement

ESMO Latest

ESMO

ESMO 2020 Conference Highlights eBOOK

Dec 23, 2020

ESMO 2020 Lung Cancer Conference Report In Focus: Lung Cancer Durvalumab Demonstrates...

Amivantamab-Lazertinib Combo for Resistant EGFR-positive NSCLC

Nov 25, 2020
4-Year PACIFIC Data Hold Strong for Durvalumab in NSCLC

Oct 27, 2020
Phase III ADAURA Trial: CNS Recurrences slashed for NSCLC

Oct 21, 2020
ESMO: Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC

Sep 24, 2020

ESMO: Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade)

Sep 24, 2020

Several clinical trials have showed that combining an anti-CTLA-4 inhibitor and an anti-PD-(L)1...

ESMO: PD-L1 density, a new predictive biomarker in NSCLC

Sep 24, 2020
ESMO: Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence

Sep 24, 2020
ESMO: No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC

Sep 24, 2020
ESMO: Is adding an immune checkpoint inhibitor to targeted therapy the right approach?

Sep 24, 2020

Advertisement